Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lycera Expands Pact With Merck

by Ann M. Thayer
February 18, 2013 | A version of this story appeared in Volume 91, Issue 7

Lycera has expanded its collaboration with Merck & Co. to develop small-molecule drugs against autoimmune diseases. In 2011, the companies began work on immune modulators targeting the retinoic acid-related orphan receptor. Under the new agreement, Merck will pay an up-front fee, provide research funding, and make up to $300 million in milestone payments. In addition, Merck will handle clinical development and commercialization of any resulting products. Lycera is a 2006 spin-off of the University of Michigan.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.